Varda Space Industries just took over a 100,000-square-foot facility in El Segundo that used to churn out Barbie dolls and Hot Wheels. It's a poetic shift. Instead of plastic toys, this space will now house the production of high-value pharmaceuticals cooked in the microgravity of low Earth orbit. The move isn't just about getting more elbow room. It's a signal that the "space-for-earth" economy is moving out of the experimental phase and into a serious industrial scale.
The company, co-founded by former SpaceX engineer Will Bruey and Founders Fund partner Delian Asparouhov, is betting everything on a simple scientific truth. Gravity is a bug, not a feature, when you're trying to grow perfect crystals. When you remove gravity from the equation, you eliminate convection and sedimentation. This allows for the creation of protein crystals and thin films with a level of precision that's physically impossible on the ground.
Why El Segundo is the new orbital manufacturing hub
Location matters. El Segundo has quietly become the "Gaviota Coast" of the NewSpace world. By snagging the former Mattel plant at 1955 East Grand Avenue, Varda puts itself within a stone's throw of SpaceX, Northrop Grumman, and the Los Angeles Air Force Base. This isn't just about being near the "cool kids" in aerospace. It's about the supply chain.
When you're building reentry capsules that need to survive a 17,000-mph plunge through the atmosphere, you need specialized machinists. You need thermal protection experts. You need people who know how to handle hydrazine. All that talent lives in the South Bay. Varda’s expansion into this massive footprint shows they're moving beyond the "move fast and break things" startup vibe and into a phase where they need serious infrastructure. They're growing from a small team in a cramped shop to an industrial powerhouse with room for hundreds of engineers.
The business of making drugs in the stars
Most people think space business is about satellites or Mars colonies. Varda thinks it’s about the medicine cabinet. Their primary focus is on life sciences, specifically improving the bioavailability of drugs.
Take Ritonavir, a common medication used to treat HIV and more recently COVID-19. In their first mission, Varda successfully processed Ritonavir in orbit and brought it back. The results were clear. The crystals formed in space were different—often better—than those made on Earth. By tweaking the crystalline structure of a drug, pharma companies can potentially make versions that are easier to swallow, last longer on the shelf, or are absorbed more effectively by the human body.
Breaking down the mission profile
The Varda model doesn't rely on the International Space Station (ISS). That's a huge distinction. Using the ISS is slow. It’s bogged down by bureaucracy and the safety requirements of having humans on board. Varda’s approach is entirely robotic.
- The Bus: They use a Rocket Lab Photon spacecraft to provide power, propulsion, and communication.
- The Lab: Their proprietary hardware conducts the chemical formulations automatically.
- The Capsule: A small, rugged reentry vehicle protects the cargo during the trip back home.
This "shuttle" system is designed to be frequent. They aren't looking for one-off wins. They want a conveyor belt of capsules dropping into the desert, each carrying millions of dollars worth of refined medicine.
Gravity is the enemy of chemistry
On Earth, if you mix two liquids of different densities, the heavy stuff sinks. That’s sedimentation. As you heat a liquid, the warm part rises and the cool part sinks. That’s convection. These forces create "noise" in the molecular assembly process.
In microgravity, these forces vanish. Molecules stay exactly where you put them. For a chemist, this is like moving from a noisy construction site into a soundproof room. You can suddenly see and control the fine details of how a drug’s crystalline structure forms. This leads to "polymorphs"—different physical forms of the same chemical—that simply cannot exist under the thumb of Earth’s 1g environment.
Chasing the 2026 launch manifest
Varda isn't sitting on its hands while it renovates the Mattel plant. They've already proven they can bring a capsule back. Their first mission, W-1, landed in Utah in early 2024 after some regulatory back-and-forth with the FAA. That landing was the "Kitty Hawk" moment for space manufacturing. It proved that the heat shield worked, the parachutes deployed, and the cargo survived.
Now, the focus is on cadence. To make the economics work, Varda needs to launch often. The new El Segundo facility allows them to build multiple capsules simultaneously. It gives them the space to integrate their laboratories into the spacecraft without tripping over each other. They’re aiming for a future where space-made drugs aren't a novelty but a standard part of the pharmaceutical supply chain.
The regulatory hurdle remains
If there's a bottleneck, it isn't the science. It’s the paperwork. The FAA and the Air Force are still figuring out how to handle private companies dropping "parcels" from space onto US soil. Varda spent months waiting for the green light for their first recovery. While they've since streamlined that process, the regulatory environment is still catching up to the technology. Moving to El Segundo puts them closer to the regulators and the military partners who manage the Western Range, which helps smooth those conversations.
Why this matters to you
You might never go to space, but there’s a high probability you’ll eventually take a drug that was developed or refined there. We’re looking at a shift where "Made in Space" becomes a premium label for high-tech materials and life-saving medicine. Varda’s new factory is the first step in making that a commercial reality.
If you’re watching the space industry, stop looking at the rockets and start looking at the cargo. The rocket is just the delivery truck. The real value is in the 100 kilograms of white powder inside the capsule. Varda is building the factory that builds the labs that make that powder.
Keep an eye on the upcoming launch schedules for 2026. The next few missions will determine if Varda can turn this massive El Segundo footprint into a profitable orbital assembly line. If you're an investor or just a tech enthusiast, track their recovery success rate. That’s the only metric that actually counts. If the capsule doesn't come home, the science doesn't matter.
Check the FAA's commercial space transportation filings for Varda's next reentry license. That's the best way to see when the next batch of space-crystals is headed for the desert.
